U.S. Markets close in 4 hrs 22 mins

Kindred Biosciences, Inc. (KIN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.7900-0.0400 (-0.83%)
As of 11:35AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.8300
Open4.8500
Bid4.7600 x 2200
Ask4.7400 x 1000
Day's Range4.7100 - 4.9500
52 Week Range3.2000 - 6.0000
Volume207,417
Avg. Volume478,586
Market Cap205.119M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.5550
Earnings DateMar 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.18
  • Kindred Biosciences Unveils Positive Results from its Long-Acting Interleukin-31 Antibody PK Study
    PR Newswire

    Kindred Biosciences Unveils Positive Results from its Long-Acting Interleukin-31 Antibody PK Study

    Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a new long-acting interleukin (IL)-31 antibody program (KIND-039) that integrates the company's novel half-life extension technology. Results from the pharmacokinetic study of the molecule demonstrate that the fully caninized, high-affinity antibody has up to a three-fold longer half-life compared to tirnovetmab. This extended half-life is expected to allow for up to three-fold longer interval between dosing.

  • Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates
    Zacks

    Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates

    Kindred Bio (KIN) delivered earnings and revenue surprises of 15.15% and -0.94%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Kindred Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results
    PR Newswire

    Kindred Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results

    Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided updates on its programs. For the fourth quarter of 2020, KindredBio reported net revenues of $1.0 million and a net loss of $10.9 million, or $0.28 per share. For the full year 2020, net product revenues were $42.2 million and the net loss was $21.8 million, or $0.55 per share.